Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Helicobacter Pylori Diagnostics market in this environment.
In terms of revenue, this research report indicated that the global Helicobacter Pylori Diagnostics market was valued at USD XXX million in 2020, and it is expected to reach a value of USD XXX million by 2027, at a CAGR of XX % over the forecast period 2021-2027. Correspondingly, the forecast analysis of Helicobacter Pylori Diagnostics industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Bio-Rad aims at producing XX K Units Helicobacter Pylori Diagnostics in 2020, with XX % production to take place in global market, Daiichi accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2026-2027) of Helicobacter Pylori Diagnostics Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Helicobacter Pylori Diagnostics Market
Bio-Rad
Daiichi
Biotest
Tosho
Trinity Biotech
Roche
Innogenetics
Enzo Biochem
Binding Site
Biomerica
Coris BioConcept
EKF Diagnostics
LifeSign PBM
...
Major Type of Helicobacter Pylori Diagnostics Covered in Prudent Markets report:
Blood Antibody Test
Urea Breath Test
Stool Antigen Test
Stomach Biopsy
Application Segments Covered in Prudent Markets Market
Hospitals and Clinics
Diagnostic Laboratories
Application 3
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Helicobacter Pylori Diagnostics Market Analysis 2021, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Blood Antibody Test -Product Introduction and Major Manufacturers
1.1.2 Urea Breath Test -Product Introduction and Major Manufacturers
1.1.3 Stool Antigen Test -Product Introduction and Major Manufacturers
1.1.4 Stomach Biopsy -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Helicobacter Pylori Diagnostics Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2026-2027)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2026-2027)
2.3 Application Breakdown Estimates & Forecast, by Application (2026-2027)
3 Regional Market Analysis
3.1 China Helicobacter Pylori Diagnostics Market
3.1.1 Top Companies leading Helicobacter Pylori Diagnostics Development in China (2016-2021)
3.1.2 Sales Value of Major Company in China Market (2016-2021)
3.1.3 China Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2026-2027)
3.2 EU Helicobacter Pylori Diagnostics Market
3.2.1 Top Companies leading Helicobacter Pylori Diagnostics Development in EU (2016-2021)
3.2.2 Sales Value of Major Company in EU Market (2016-2021)
3.2.3 EU Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2026-2027)
3.3 USA Helicobacter Pylori Diagnostics Market
3.3.1 Top Companies leading Helicobacter Pylori Diagnostics Development in USA (2016-2021)
3.3.2 Sales Value of Major Company in USA Market (2016-2021)
3.3.3 USA Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2026-2027)
3.4 Japan Helicobacter Pylori Diagnostics Market
3.4.1 Top Companies leading Helicobacter Pylori Diagnostics Development in Japan (2016-2021)
3.4.2 Sales Value of Major Company in Japan Market (2016-2021)
3.4.3 Japan Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2026-2027)
3.5 India Helicobacter Pylori Diagnostics Market
3.5.1 Top Companies leading Helicobacter Pylori Diagnostics Development in India (2016-2021)
3.5.2 Sales Value of Major Company in India Market (2016-2021)
3.5.3 India Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2026-2027)
3.6 Southeast Asia Helicobacter Pylori Diagnostics Market
3.6.1 Top Companies leading Helicobacter Pylori Diagnostics Development in Southeast Asia (2016-2021)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2016-2021)
3.6.3 Southeast Asia Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2026-2027)
3.7 South America Helicobacter Pylori Diagnostics Market
3.7.1 Top Companies leading Helicobacter Pylori Diagnostics Development in South America (2016-2021)
3.7.2 Sales Value of Major Company in South America Market (2016-2021)
3.7.3 South America Helicobacter Pylori Diagnostics Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2026-2027)
4 Value Chain (Impact of COVID-19)
4.1 Helicobacter Pylori Diagnostics Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Helicobacter Pylori Diagnostics Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2027)
5.1 Global Helicobacter Pylori Diagnostics Sales and Growth Rate (2021-2027)
5.2 Global Helicobacter Pylori Diagnostics Sales Value and Growth Rate (2021-2027)
6 Helicobacter Pylori Diagnostics Competitive Analysis
6.1 Bio-Rad
6.1.1 Bio-Rad Company Profiles
6.1.2 Bio-Rad Product Introduction
6.1.3 Bio-Rad Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.1.4 SWOT Analysis
6.2 Daiichi
6.2.1 Daiichi Company Profiles
6.2.2 Daiichi Product Introduction
6.2.3 Daiichi Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.2.4 SWOT Analysis
6.3 Biotest
6.3.1 Biotest Company Profiles
6.3.2 Biotest Product Introduction
6.3.3 Biotest Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.3.4 SWOT Analysis
6.4 Tosho
6.4.1 Tosho Company Profiles
6.4.2 Tosho Product Introduction
6.4.3 Tosho Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.4.4 SWOT Analysis
6.5 Trinity Biotech
6.5.1 Trinity Biotech Company Profiles
6.5.2 Trinity Biotech Product Introduction
6.5.3 Trinity Biotech Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.5.4 SWOT Analysis
6.6 Roche
6.6.1 Roche Company Profiles
6.6.2 Roche Product Introduction
6.6.3 Roche Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.6.4 SWOT Analysis
6.7 Innogenetics
6.7.1 Innogenetics Company Profiles
6.7.2 Innogenetics Product Introduction
6.7.3 Innogenetics Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.7.4 SWOT Analysis
6.8 Enzo Biochem
6.8.1 Enzo Biochem Company Profiles
6.8.2 Enzo Biochem Product Introduction
6.8.3 Enzo Biochem Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.8.4 SWOT Analysis
6.9 Binding Site
6.9.1 Binding Site Company Profiles
6.9.2 Binding Site Product Introduction
6.9.3 Binding Site Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.9.4 SWOT Analysis
6.10 Biomerica
6.10.1 Biomerica Company Profiles
6.10.2 Biomerica Product Introduction
6.10.3 Biomerica Helicobacter Pylori Diagnostics Production, Revenue (2016-2021)
6.10.4 SWOT Analysis
6.11 Coris BioConcept
6.12 EKF Diagnostics
6.13 LifeSign PBM
7 Conclusion